Xiaolan Yong
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Journal: Lancet (London, England)
Published: June 13, 2026
Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double-Blind, Single-Dose, Parallel-Group Study in Healthy Chinese Participants.
Journal: Clinical pharmacology in drug development
Published: February 06, 2026
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: November 17, 2025
Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months.
Journal: Scientific reports
Published: June 10, 2025
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment.
Journal: Clinical pharmacology in drug development
Published: January 13, 2025
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study.
Journal: Drug design, development and therapy
Published: October 30, 2024
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.
Journal: Human vaccines & immunotherapeutics
Published: October 19, 2023
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.
Journal: Journal of diabetes
Published: December 20, 2021
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Journal: Clinical drug investigation
Published: December 23, 2015
Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China.
Journal: Annals of clinical microbiology and antimicrobials
Published: October 08, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026